| Name | Title | Contact Details |
|---|
"Eleven uses its proprietary technology platform to create first-of-a-kind protein therapeutics to address unmet needs for ophthalmic diseases. Proteins are able to modulate inflammatory cytokines, key targets in ocular disease that have been difficult to access with conventional therapeutic approaches. A significant untapped opportunity exists for protein therapeutics to address ophthalmic diseases, and Eleven is applying its advanced protein technology and expertise to develop innovative medicines for patients suffering from ocular diseases. Eleven`s team of industry veterans has deep experience in understanding protein science and biologic drug development, designing and conducting clinical trials and, most importantly, applying specific expertise in ophthalmic disease to create novel ocular therapeutics to treat unmet medical needs. Eleven has developed a proprietary pipeline of ophthalmic drug candidates derived from the company`s innovative AMP-Rx protein engineering technology. The company`s initial product candidates are focused on targeting inflammatory cytokines and key targets of ocular disease by blocking the cytokines and modulating the biological processes that drive ocular disease. Current pipeline opportunities include ocular surface diseases such as dry eye disease (DED) and allergic conjunctivitis (AC), and back of the eye diseases such as diabetic macular edema (DME) and uveitis. In addition, Eleven’s proprietary technology has been utilized to prolong the intravitreal half-life of our pipeline products. Beyond its internal drug development programs, Eleven works with collaborators, such as ThromboGenics, to apply its innovative protein therapeutic design capabilities to engineer and develop biotherapeutic products for additional therapeutic targets. EBI-005, Eleven`s lead product candidate, is a novel interleukin-1 (IL-1) receptor antagonist in Phase 3 clinical development as one of the first topically administered proteins for the treatment of DED and AC, two inflammatory diseases at the surface of the eye."
ALZYN is a development stage company pursuing a unique approach to retard the progress of Alzheimer`s Disease. The science originated at the Florida State University`s College of Medicine.
Outlook Associates, Inc. is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Beaumont Health is a not-for-profit organization formed by Beaumont Health System, Botsford Health Care and Oakwood Healthcare to provide high quality, efficient, accessible services in a caring environment for southeastern Michigan residents and beyond. It consists of eight hospitals with 3,337 beds, 153 outpatient sites, 5,000 physicians, more than 33,000 employees and about 3,500 volunteers. In 2013, the combined organizations had 168,047 inpatient admissions, 15,997 births and 492,677 emergency visits.
Heritage Enterprises Inc. is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. Heritage Enterprises Inc. is based in Bloomington, IL. You can find more information on Heritage Enterprises Inc. at www.heritageofcare.com